If cancer exhibits a weakness, exploit it before taking the target away.
Clinical Trials
Melanoma subtype influences immune-related adverse events in ICI therapy
Cutaneous immune-related adverse events are highly dependent on melanoma subtype among immune checkpoint inhibitor therapy recipients, according to a study.
Timing of Melanoma Immunotherapy Could Be Key to Outcomes: Study
MONDAY, March 6, 2023 (HealthDay News) — A tweak in timing may make an immune-system therapy much more effective for patients undergoing surgery for advanced melanoma, a new clinical trial has found.
Results From the C-144-01 Trial and Potential Impact on Clinical Practice
Amod Sarnaik, MD: The next abstract we would like to discuss is a multicenter, single-arm, phase 2 study involving TILs [tumor-infiltrating lymphocytes] in the treatment of advanced treatment-refractory melanoma.